Comparative analysis of methods for detecting isocitrate dehydrogenase 1 and 2 mutations and their metabolic consequence, 2-hydroxyglutarate, in different neoplasms

Applied Immunohistochemistry and Molecular Morphology

Volumn 25, Issue 5, 2017, Pages 334-337

  Babakoohi, Shahab ^a,b   Lapidus, Rena G ^a   Faramand, Rawan ^a   Sausville, Edward A ^a   Emadi, Ashkan ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

2 hydroxyglutarate; AML; Immunohistochemistry; Isocitrate dehydrogenase; Magnetic resonance spectroscopy

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ACUTE MYELOID LEUKEMIA; ARTICLE; BILE DUCT CARCINOMA; CHONDROSARCOMA; DNA SEQUENCE; GENE MUTATION; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; T CELL LYMPHOMA; ENZYMOLOGY; GENETICS; METABOLISM; MUTATION; PATHOPHYSIOLOGY; STANDARDS;

GLUTARATES; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; MASS SPECTROMETRY; MUTATION; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84960156318     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000342     Document Type: Article

References (34)

1. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013; 3: 730-741
2. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013; 27: 836-852
3. Rohle D, Popovici-Muller J, Palaskas N, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013; 340: 626-630
4. Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013; 340: 622-626
5. Emadi A, Jun SA, Tsukamoto T, et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol. 2014; 42: 247-251
6. Kaneko MK, Tian W, Takano S, et al. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Bioch Biophys Res Commun. 2011; 406: 608-613
7. Mellai M, Piazzi A, Caldera V, et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol. 2011; 105: 345-357
8. Loussouarn D, Le Loupp AG, Frenel JS, et al. Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. Int I Oncol. 2012; 40: 2058-2062
9. Preusser M, Wohrer A, Stary S, et al. Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens. J Neuropathol Exp Neurol. 2011; 70: 715-723
10. Esmaeili M, Vettukattil R, Bathen TF. 2-hydroxyglutarate as a magnetic resonance biomarker for glioma subtyping. Transl Oncol. 2013; 6: 92-98
11. Fathi AT, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012; 120: 4649-4652
12. Meyer J, Pusch S, Balss J, et al. PCR- and restriction endonucleasebased detection of IDH1 mutations. Brain Pathol. 2010; 20: 298-300
13. Thota B, Shukla SK, Srividya MR, et al. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance. Am J Clini Pathol. 2012; 138: 177-184
14. Patel KP, Barkoh BA, Chen Z, et al. Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis. J Mol Diagn: JMD. 2011; 13: 678-686
15. Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncol. 2013; 15: 718-726
16. Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010; 20: 245-254
17. Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011; 28: 115-123
18. Kato Y, Natsume A, Kaneko MK. A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochemical Biophys Res Commun. 2013; 432: 564-567
19. Kaneko MK, Morita S, Tsujimoto Y, et al. Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochemical Biophys Res Commun. 2013; 432: 40-45
20. Kato Kaneko M, Ogasawara S, Kato Y. Establishment of a multispecific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. Tohoku J Exp Med. 2013; 230: 103-109
21. Felsberg J, Wolter M, Seul H, et al. Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010; 119: 501-507
22. Van den Bent MJ, Hartmann C, Preusser M, et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol. 2013; 112: 173-178
23. DiNardo CD, Propert KJ, Loren AW, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013; 121: 4917-4924
24. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010; 18: 553-567
25. Capper D, Simon M, Langhans CD, et al. 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer. 2012; 131: 766-768
26. Choi C, Ganji SK, DeBerardinis RJ, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012; 18: 624-629
27. Andronesi OC, Kim GS, Gerstner E, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012; 4: 116ra4
28. Pope WB, Prins RM, Albert Thomas M, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012; 107: 197-205
29. Popovici-Muller J, Saunders JO, Salituro FG, et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett. 2012; 3: 850-855
30. Quail MA, Smith M, Coupland P, et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers. BMC Genomics. 2012; 13: 341-353
31. Luo C, Tsementzi D, Kyrpides N, et al. Direct comparisons of Illumina vs. Roche 454 sequencing technologies on the same microbial community DNA sample. PLoS One. 2012; 7: e30087
32. Suzuki S, Ono N, Furusawa C, et al. Comparison of sequence reads obtained from three next-generation sequencing platforms. PLoS One. 2011; 6: e19534
33. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013; 19: 764-772
34. Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013; 339: 1621-1625